Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1). CEACAM1 is a immune modulator blocking its interactions could strengthen immune cells' attack on cancer.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Fano
  • Italy

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.

Request full access to PitchBook

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.

Request full access to PitchBook